Zymeworks Presents Results of the Completed Dose Escalation Portion of the Ongoing Phase 1 Study of ZW25 at the San Antonio Breast Cancer Symposium
Zymeworks Inc. (ZYME)
Last zymeworks inc. earnings: 3/2 04:15 pm
Check Earnings Report
US:NYSE Investor Relations:
ir.zymeworks.com/overview
Company Research
Source: Business Wire
Continued Clinical Benefit of Single Agent ZW25 in Heavily Pretreated HER2-High Patients VANCOUVER, British Columbia--(BUSINESS WIRE)-- Zymeworks Inc. (NYSE/TSX: ZYME), a clinical-stage biopharmaceutical company dedicated to the development of next-generation multifunctional biotherapeutics, today presented the completed dose escalation portion of its Phase 1 study of ZW25, a novel Azymetric™ bispecific antibody targeting two distinct domains of the HER2 receptor. The HER2–mediated signaling pathway is believed to contribute to tumor growth in a number of cancers. A total of 22 patients have been enrolled in the study, including 11 with breast cancer, eight with gastric, gastroesophageal junction, or esophageal (GE) cancer, and three with other HER2-expressing cancers. Part one of the multi-part study was a standard dose escalation where patients received ZW25 either weekly at 5 mg/kg (n=3), 10 m
Show less
Read more
Impact Snapshot
Event Time:
ZYME
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ZYME alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ZYME alerts
High impacting Zymeworks Inc. news events
Weekly update
A roundup of the hottest topics
ZYME
News
- Zymeworks Inc. (NYSE: ZYME) had its price target lowered by analysts at Citigroup Inc. from $17.00 to $16.00. They now have a "buy" rating on the stock.MarketBeat
- Zymeworks Inc. (NYSE: ZYME) had its price target lowered by analysts at Wells Fargo & Company from $14.00 to $12.00. They now have an "overweight" rating on the stock.MarketBeat
- Zymeworks Inc. (NYSE:ZYME) Q1 2024 Earnings Call Transcript [Yahoo! Finance]Yahoo! Finance
- Lost Money on Zymeworks Inc.(ZYME)? Contact Levi & Korsinsky Regarding an Ongoing InvestigationAccesswire
- Zymeworks Inc. (ZYME) Reports Q1 Loss, Misses Revenue Estimates [Yahoo! Finance]Yahoo! Finance
ZYME
Earnings
- 5/2/24 - Miss
ZYME
Sec Filings
- 5/3/24 - Form 8-K
- 5/3/24 - Form 424B5
- 5/3/24 - Form 424B5
- ZYME's page on the SEC website